Clinical trials: EC905
Drug-Drug Interaction (DDI), Healthy Subjects
A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet
This study investigates the effect of the co-administration of verapamil on the steady-state pharmacokinetics (PK) of solifenacin succinate and tamsulosin given as a combination tablet, EC905.
- Trial name
- NCT01943487
- Testing
- EC905, verapamil
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
EC905, Pharmacokinetics
A Study to Evaluate Whether Food Has an Effect on the Uptake of Solifenacin and Tamsulosin When Administered in a Combination Tablet
To evaluate the effect of food (low and high fat breakfast vs. fasting) on the pharmacokinetics (what the body does to the drug) of a single dose of solifenacin and tamsulosin administered as combination tablet EC905.
- Conditions
- EC905, Pharmacokinetics, Healthy Subjects
- Trial name
- NCT01953861
- Testing
- EC905
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
EC905, Pharmacokinetics
A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin
A study to assess the amount of drug in the blood of young to middle aged, healthy, male subjects after they received the final formulation of EC905 compared to solifenacin (Vesicare®) and tamsulosin OCAS (Omnic OCAS®).
- Conditions
- EC905, Pharmacokinetics, Healthy Subjects
- Trial name
- NCT01953887
- Testing
- EC905, solifenacin, tamsulosin
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Phase 1, Healthy
EC905 Pharmacokinetic Profile Study
A study to compare the pharmacokinetics of tamsulosin HCl and solifenacin succinate after co-administration of single entity tablets and of the combination tablet EC905 under steady state conditions at three dose strengths.
- Conditions
- Phase 1, Healthy, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
- Trial name
- NCT02634489
- Testing
- Tamsulosin HCl, Solifenacin Succinate, EC905
- Where
- Netherlands
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
EC905, Pharmacokinetics
A Study to Evaluate How Tamsulosin (at 1 Dose) and Solifenacin (at 2 Different Doses) Are Taken up From the Intestine, Distributed Through the Body and Eliminated From the Body When Administered in Combination as a Single Tablet (Called EC905)
Tamsulosin (sold under the name Omnic OCAS) is used for treatment of voiding complaints related to an enlarged prostate. Solifenacin (sold under the name Vesicare) is used for the treatment of patients suffering from problems…
- Conditions
- EC905, Pharmacokinetics, Multiple Dose, Healthy Subjects
- Trial name
- NCT01953848
- Testing
- EC905
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.